Edgewise Therapeutics, Inc. Common Stock (EWTX) Stock Price

EWTXStock
$44.21+201.14%52W
Market Cap$4.80B
P/E
PEG Ratio
Div yield
Beta0.34

EWTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)37.08%
Price vs S&P 500 (4W)7.78%
VGM Score80.18

EWTX Earnings Surprise History

Q2 25-0.34est. -0.42
Q3 25-0.39est. -0.40
Q4 25-0.47est. -0.44
Q1 26-0.46est. -0.48
Q2 26-0.53est. -0.47

EWTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.17
4.17
4.17
4.21

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
EWTXEdgewise Therapeutics, Inc. Common Stock
A$44.21
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Edgewise Therapeutics, Inc. Common Stock

Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and cardiac conditions. Its lead candidate, Sevasemten, is an oral small molecule designed to address the root cause of dystrophinopathies, including Duchenne and Becker muscular dystrophy. The company is advancing additional product candidates targeting muscle disease across its pipeline.